Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-ala-6-arg-leu-enkephalin
2. Enkephalin, Ala(2)-leu(5)-arg(6)-
3. Enkephalin-leu, Ala(2)-arg(6)-
4. Enkephalin-leu, Ala(2)-arg(6)-, (d-arg-l-tyr-d-ala-l-phe-d-leu)-isomer
5. Enkephalin-leu, Ala(2)-arg(6)-, (d-arg-l-tyr-d-ala-l-phe-l-leu)-isomer
6. Enkephalin-leu, Ala(2)-arg(6)-, (l-arg-l-tyr-d-ala-l-phe-d-leu)-isomer
7. Enkephalin-leu, Alanyl(2)-arginine(6)-
8. Leu-enkephalin, Ala(2)-arg(6)-
9. Leucine-enkephalin, Ala(2)-arg(6)-
10. Tageflar
11. Tyr-ala-gly-phe-leu-arg
12. Tyrosyl-alanyl-glycyl-phenylalanyl--leucyl-arginine
1. 81733-79-1
2. Tyr-d-ala-gly-phe-leu-arg
3. (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic Acid
4. Tageflar
5. V13505565p
6. Enkephalin-leu, Ala(2)-arg(6)-
7. (d-ala2)-leu-enkephalin-arg
8. Unii-v13505565p
9. (d-ala2)-leucine Enkephalin-arg
10. Dalargine
11. Brn 4287455
12. 2-d-alanine-1-6-beta-neoendorphin (human)
13. Dalargin [who-dd]
14. Tyrosyl-d-alanyl-glycyl-phenylalanyl-leucyl-arginine
15. Dtxsid50231302
16. 1-6-(d-ala2)-dynorphin
17. Ex-a5715
18. H-tyr-d-ala-gly-phe-leu-arg-oh
19. Zinc53255341
20. N(sup 2)-(n-(n-(n-(l-tyrosyl-d-alanyl)glycyl)-l-phenylalanyl)-l-leucyl)-l-arginine
21. 1-6-beta-neoendorphin (human), 2-d-alanine-
22. Q27291394
23. 1-6-.beta.-neoendorphin (human), 2-d-alanine-
24. L-arginine, L-tyrosyl-d-alanylglycyl-l-phenylalanyl-l-leucyl-
25. L-arginine, N(sup 2)-(n-(n-(n-(l-tyrosyl-d-alanyl)glycyl)-l-phenylalanyl)-l-leucyl)-
26. (2s,5s,8s,14r,17s)-17-amino-8-benzyl-2-(3-guanidinopropyl)-18-(4-hydroxyphenyl)-5-isobutyl-14-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaoctadecan-1-oic Acid
| Molecular Weight | 725.8 g/mol |
|---|---|
| Molecular Formula | C35H51N9O8 |
| XLogP3 | -2.5 |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 21 |
| Exact Mass | 725.38605962 g/mol |
| Monoisotopic Mass | 725.38605962 g/mol |
| Topological Polar Surface Area | 293 Ų |
| Heavy Atom Count | 52 |
| Formal Charge | 0 |
| Complexity | 1210 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Antioxidants
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
ABOUT THIS PAGE
A Dalargin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dalargin, including repackagers and relabelers. The FDA regulates Dalargin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dalargin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dalargin supplier is an individual or a company that provides Dalargin active pharmaceutical ingredient (API) or Dalargin finished formulations upon request. The Dalargin suppliers may include Dalargin API manufacturers, exporters, distributors and traders.
Dalargin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dalargin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dalargin GMP manufacturer or Dalargin GMP API supplier for your needs.
A Dalargin CoA (Certificate of Analysis) is a formal document that attests to Dalargin's compliance with Dalargin specifications and serves as a tool for batch-level quality control.
Dalargin CoA mostly includes findings from lab analyses of a specific batch. For each Dalargin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dalargin may be tested according to a variety of international standards, such as European Pharmacopoeia (Dalargin EP), Dalargin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dalargin USP).
LOOKING FOR A SUPPLIER?
